Second Sight wins go-ahead for German Argus II study
Our client, Second Sight Medical, have won approval from Germany’s BfArM regulatory body to initiate a 10-patient study exploring the use of its Argus II retinal prosthesis system in better sighted retinitis pigmentosa patients and individuals with tunnel vision.
Retinitis pigmentosa is the name given to a group of inherited conditions of the retina that lead to a gradual progressive reduction in vision. Argus II induces visual perception in patients with retinitis pigmentosa by stimulating of the retina’s remaining cells with electrical pulses, which allows for the perception of light patterns to the brain. The clinical trial will take place at 3 sites across Germany.
Stephen Carter and his patent team work with Second Sight Medical on their IP portfolio.